Ligand Pharmaceuticals Incorporated
Stock Forecast, Prediction & Price Target
Ligand Pharmaceuticals Incorporated (LGND) stock Price Target by analysts
$146
Potential downside: -2.04%
Ligand Pharmaceuticals Incorporated price prediction
What is Ligand Pharmaceuticals Incorporated stock analysts` prediction?
Ligand Pharmaceuticals Incorporated stock forecast: Based on 2 Wall Street analysts` predicted price targets for Ligand Pharmaceuticals Incorporated in the last 3 months, the avarage price target is $146, with a high forecast of $NaN. The average price target represents a -2.04% change from the last price of $149.05.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Ligand Pharmaceuticals Incorporated stock Price Target by analysts
Full breakdown of analysts given Ligand Pharmaceuticals Incorporated price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Joseph Pantginis H.C. Wainwright | 0% 0/2 | 11 months ago | $157 5.33% upside | $108.31 | StreetInsider | Previous targets (1) |
Leland Gershell Oppenheimer | 0% 0/1 | 11 months ago | $135 -9.42% downside | $99.95 | TheFly | Previous targets (0) |
Douglas Miehm RBC Capital | 0% 0/1 | about 1 year ago | $130 -12.78% downside | $108.75 | StreetInsider | Previous targets (0) |
Matt Hewitt Craig-Hallum | 0% 0/1 | about 1 year ago | $140 -6.07% downside | $86.88 | TheFly | Previous targets (0) |
Joseph Pantginis H.C. Wainwright | 0% 0/2 | about 1 year ago | $144 -3.38% downside | $82.33 | StreetInsider | Previous targets (1) |
Unknown Roth Capital | N/A | over 2 years ago | $90 -39.61% downside | $67.32 | Benzinga | N/A |
Ligand Pharmaceuticals Incorporated Financial Estimates
Ligand Pharmaceuticals Incorporated Revenue Estimates
Ligand Pharmaceuticals Incorporated EBITDA Estimates
Ligand Pharmaceuticals Incorporated Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | |
Revenue
% change YoY
| $277.13M N/A | $196.24M -29.18% | $131.31M -33.08% | Avg: $157.46M Low: $154.66M High: $160.26M avg. 19.91% | Avg: $192.08M Low: $187.08M High: $197.83M avg. 21.98% | Avg: $194.66M Low: $189.59M High: $200.49M avg. 1.34% | |
Net Income
% change YoY
| $57.13M N/A | $-5.21M -109.13% | $52.15M 1099.31% | Avg: $50.89M Low: $45.63M High: $68.89M avg. -2.40% | Avg: $132.11M Low: $127.64M High: $137.25M avg. 159.55% | Avg: $151.82M Low: $146.68M High: $157.72M avg. 14.91% | |
EBITDA
% change YoY
| $117.20M N/A | $8.73M -92.54% | $101.72M 1064.72% | Avg: $916.72K Low: $900.39K High: $933K avg. -99.09% | Avg: $1.11M Low: $1.08M High: $1.15M avg. 21.98% | Avg: $1.13M Low: $1.10M High: $1.16M avg. 1.34% | |
EPS
% change YoY
| $3.44 N/A | -$0.31 -109.01% | $3.02 1074.19% | Avg: $3.23 Low: $2.57 High: $3.88 avg. 6.78% | Avg: $7.44 Low: $7.19 High: $7.73 avg. 130.69% | Avg: $8.55 Low: $8.26 High: $8.88 avg. 14.91% | |
Operating Expenses
% change YoY
| $136.06M N/A | $140.38M 3.17% | $84.32M -39.93% | Avg: $52.28M Low: $51.35M High: $53.21M avg. -37.98% | Avg: $63.78M Low: $62.12M High: $65.69M avg. 21.98% | Avg: $64.64M Low: $62.95M High: $66.57M avg. 1.34% | |
FAQ
What is Ligand Pharmaceuticals Incorporated stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 57.35% in 2025-2027.
We have gathered data from 2 analysts. Their low estimate is 45.63M, average is 50.89M and high is 68.89M.
What is Ligand Pharmaceuticals Incorporated stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 14.41% in 2025-2027.
We have gathered data from 3 analysts. Their low revenue estimate is $154.66M, average is $157.46M and high is $160.26M.
What is Ligand Pharmaceuticals Incorporated stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 50.80% in 2025-2027.
We have gathered data from 2 analysts. Their low earnings per share estimate is $2.57, average is $3.23 and high is $3.88.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Ligand Pharmaceuticals Incorporated stock. The most successful analyst is Joseph Pantginis.